Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3910

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 157–168 of 3,910 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions: Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy; Procedure · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
Interventions: LY4257496, Standard of Care Anticancer Therapies, LY4257529; Drug · Diagnostic Test
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 16
States / cities: Duarte, California • Santa Monica, California • Stanford, California + 11 more

Conditions: Prostate Cancer, Prostate Neoplasms
Interventions: ultrasound image-guided ablation device; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: fluciclovine (18F); Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions: Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Duarte, California • Los Angeles, California • Orange, California + 24 more

Conditions: Prostate Carcinoma
Interventions: Exercise Intervention, Methylphenidate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Stretching; Behavioral · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, High-risk Prostate Cancer
Interventions: Darolutamide, Pembrolizumab, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Interviews, Surveys; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Recurrent Prostate Cancer, Prostate Cancer
Interventions: N-803, ETBX-71 Vaccine, 18F-DCFPyL; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions: GDC-1261; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Scottsdale, Arizona • Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: walnuts, usual diet, phone counseling with dietitian; Other
Lead sponsor: Stephen Freedland; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Fusion Guided Focal Laser Ablation of Prostate Cancer

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing

FOG-001 in Locally Advanced or Metastatic Solid Tumors

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

About this Prostate Cancer clinical trials directory page